Journal reviews avian flu vaccine

DEERFIELD - Baxter International Inc. said Thursday's issues of The New England Journal of Medicine will show data demonstrating that Baxter's candidate avian influenza vaccine, called Celvapan, has met Phase I/II trials for safety and has generated a functional immune response. This is the first peer-reviewed publication of study results for Celvapan, the first cell culture-derived avian influenza vaccine to undergo clinical evaluation.